What does this research mean for the field?

Capecitabine combined with docetaxel is more clinically effective and likely more cost-effective than single-agent docetaxel for advanced breast cancer, whereas evidence for the efficacy of capecitabine monotherapy remains inconclusive due to poor study quality. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 1, 2004Health Technology AssessmentOpen Access

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer

View Full Paper

Ask AI

Bookmark

Authors

LJLisa JonesUniversity of New Hampshire NHNeil HawkinsFinancial Network Analytics (United Kingdom)MWMarie WestwoodAt Bristol

Discussion

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jones et al. (2004) studied this question.

synapsesocial.com/papers/6a6bded5050bc01bbbcb891a https://doi.org/10.3310/hta8050

View Full Paper

Ask AI

Bookmark

February 1, 2004Health Technology AssessmentOpen Access

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer

View Full Paper

Ask AI

Bookmark

Authors

LJLisa JonesUniversity of New Hampshire NHNeil HawkinsFinancial Network Analytics (United Kingdom)MWMarie WestwoodAt Bristol

Discussion

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jones et al. (2004) studied this question.

synapsesocial.com/papers/6a6bded5050bc01bbbcb891a https://doi.org/10.3310/hta8050

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark